Table 2.
Characteristics of the random sample of EPIC-NL (n=1886)
| Total (n=1886) | Men (n=465) | Women (n=1421) | |
|---|---|---|---|
| Sex (% men) |
24.6 (465) |
|
|
| Age (yr) |
50.1 (11.7) |
43.9 (11.1) |
52.2 (11.2) |
| Waist circumference (cm) |
85.5 (11.6) |
92.0 (11.4) |
82.9 (10.5) |
| Abdominal obesity(%)a |
27.7(522) |
21.9 (102) |
29.6 (420) |
| HbA1C (%) |
5.46 (0.69) |
5.27 (0.61) |
5.53 (0.71) |
| Hyperglycemiaa |
28.3 (534) |
17.8 (83) |
31.7 (451) |
| Diabetic medication(%) |
1.2 (22) |
0.2 (1) |
1.5 (21) |
| HDL-cholesterol (mmol/L) |
1.27 (0.35) |
1.14 (0.28) |
1.31 (0.36) |
| Low HDL-cholesterol(%)a |
47.8 (902) |
29.2 (136) |
53.9 (766) |
| Triglyceride (mmol/L) b, c |
1.32 (0.91-1.98) |
1.72 (1.15-2.40) |
1.22 (0.85-1.80) |
| Hypertriglyceridemia a, b |
33.8 (637) |
50.8 (236) |
28.2 (401) |
| Systolic blood pressure (mm Hg) |
126.9 (18.5) |
127.1 (14.8) |
126.8 (19.5) |
| Diastolic blood pressure (mm Hg) |
78.2 (10.4) |
80.3 (10.1) |
77.5 (10.4) |
| Hypertension(%)a |
45.6 (860) |
47.1(219) |
45.1 (641) |
| Blood pressure lowering medication (%) |
10.7 (202) |
5.6 (26) |
12.4 (176) |
| High sensitive CRP (mmol/L) |
1.41 (0.62-3.39) |
1.20 (0.53-2.82) |
1.49 (0.66-3.70) |
| MetS-score (number of features) |
1.8 (1.4) |
1.7 (1.3) |
1.9 (1.4) |
| MetS prevalence(%)a | 30.3 (572) | 25.2 (117) | 32.0 (455) |
Data are presented as means (standard deviation), median with inter-quartile range or % (n); HbA1C haemoglobin A1c, MetS metabolic syndrome, hsCRP high sensitive C-reactive protein.
aAbdominal obesity, low HDL cholesterol, hypertension, hypertriglyceridemia and MetS are defined according to the criteria of AHA-NHLBI (2005). Hyperglycemia is defined according to the criteria of the American Diabetes Association (2010). Abdominal obesity: ♂ ≥102 cm; ♀≥ 88 cm; Low HDL: ♂ <1.0; ♀<1.3 mmol/L; Hypertriglyceridemia: ≥1.7 mmol/L; Hypertension: ≥130/85 mm Hg or use of hypertensive medication; Hyperglycemia: HbA1C in National Glycohemoglobin Standarization Program (NGSP) units ≥ 5.7% or glucose lowering medication; MetS is defined as having at least 3 MetS features.
bNon-fasting values.
cNo information on lipid lowering medication is available.